Intercept Pharmaceuticals, Inc. (ICPT: Quote), which develops treatments for$ chronic liver diseases, Monday announced positive initial results from OBADIAH, an ongoing Phase 2a trial of obeticholic acid or OCA as a treatment for primary bile acid diarrhea ...
[Published RTTNews.com - 2 hours ago]